ATARA BIOTHERAPEUTICS, INC. Payments to Acquire Short-term Investments
ATARA BIOTHERAPEUTICS, INC. (ATRA) reported Payments to Acquire Short-term Investments of $6.63 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireShortTermInvestments · last filed 2026-08-12
- ATARA BIOTHERAPEUTICS, INC. payments to acquire short-term investments for the quarter ending 2025-12-31 was $0.00.
- ATARA BIOTHERAPEUTICS, INC. payments to acquire short-term investments for the quarter ending 2025-09-30 was $2.47M, a 87.46% decline year-over-year.
- ATARA BIOTHERAPEUTICS, INC. payments to acquire short-term investments for the quarter ending 2024-12-31 was $0.00, a 100.00% decline year-over-year.
- ATARA BIOTHERAPEUTICS, INC. payments to acquire short-term investments for the quarter ending 2024-09-30 was $19.66M.
- ATARA BIOTHERAPEUTICS, INC. payments to acquire short-term investments for fiscal 2025 was $7.88M, a 59.90% decline from fiscal 2024.
- ATARA BIOTHERAPEUTICS, INC. payments to acquire short-term investments for fiscal 2024 was $19.66M, a 76.49% decline from fiscal 2023.
- ATARA BIOTHERAPEUTICS, INC. payments to acquire short-term investments for fiscal 2023 was $83.65M, a 53.68% decline from fiscal 2022.
- ATARA BIOTHERAPEUTICS, INC. payments to acquire short-term investments for fiscal 2022 was $180.59M, a 40.03% decline from fiscal 2021.
| Period end | Payments to Acquire Short-term Investments 3 month | Payments to Acquire Short-term Investments 6 month | Payments to Acquire Short-term Investments 9 month | Payments to Acquire Short-term Investments 12 month |
|---|---|---|---|---|
| 2026-06-30 | $6.63M 10-Q · filed 2026-08-12 | |||
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $2.47M derived: sum of 2 quarters · filed 2026-03-16 | $7.88M 10-K · filed 2026-03-16 | |
| 2025-09-30 | $2.47M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $7.88M 10-Q · filed 2025-11-12 | ||
| 2025-06-30 | $5.42M 10-Q · filed 2026-08-12 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $19.66M derived: sum of 2 quarters · filed 2026-03-16 | $19.66M derived: sum of 3 quarters · filed 2026-03-16 | $19.66M 10-K · filed 2026-03-16 |
| 2024-09-30 | $19.66M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $19.66M derived: sum of 2 quarters · filed 2025-11-12 | $19.66M 10-Q · filed 2025-11-12 | $19.67M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $0.00 10-Q · filed 2025-08-11 | $1.00K derived: sum of 3 quarters · filed 2025-08-11 | $1.00K derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-09 | $1.00K derived: sum of 2 quarters · filed 2025-03-07 | $1.00K derived: sum of 3 quarters · filed 2025-03-07 | $15.74M derived: sum of 4 quarters · filed 2025-03-07 |
| 2023-12-31 | $1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-07 | $1.00K derived: sum of 2 quarters · filed 2025-03-07 | $15.74M derived: sum of 3 quarters · filed 2025-03-07 | $83.65M 10-K · filed 2025-03-07 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $15.74M derived: sum of 2 quarters · filed 2024-11-12 | $83.65M 10-Q · filed 2024-11-12 | $83.07M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $15.74M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $83.65M 10-Q · filed 2024-08-12 | $83.07M derived: sum of 3 quarters · filed 2024-08-12 | $99.15M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | $67.90M 10-Q · filed 2024-05-09 | $67.33M derived: sum of 2 quarters · filed 2024-05-09 | $83.40M derived: sum of 3 quarters · filed 2024-05-09 | $222.06M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | -$575.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $15.50M derived: sum of 2 quarters · filed 2024-03-28 | $154.16M derived: sum of 3 quarters · filed 2024-03-28 | $180.59M 10-K · filed 2024-03-28 |
| 2022-09-30 | $16.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-01 | $154.74M derived: sum of 2 quarters · filed 2023-11-01 | $181.16M 10-Q · filed 2023-11-01 | $257.54M derived: sum of 4 quarters · filed 2023-11-01 |
| 2022-06-30 | $138.66M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $165.09M 10-Q · filed 2023-08-08 | $241.47M derived: sum of 3 quarters · filed 2023-08-08 | $307.35M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $26.43M 10-Q · filed 2023-05-08 | $102.80M derived: sum of 2 quarters · filed 2023-05-08 | $168.69M derived: sum of 3 quarters · filed 2023-05-08 | $233.50M derived: sum of 4 quarters · filed 2023-05-08 |
| 2021-12-31 | $76.38M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-08 | $142.26M derived: sum of 2 quarters · filed 2023-02-08 | $207.07M derived: sum of 3 quarters · filed 2023-02-08 | $301.13M 10-K · filed 2023-02-08 |
| 2021-09-30 | $65.89M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $130.70M derived: sum of 2 quarters · filed 2022-11-08 | $224.75M 10-Q · filed 2022-11-08 | $371.43M derived: sum of 4 quarters · filed 2023-02-08 |
| 2021-06-30 | $64.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $158.87M 10-Q · filed 2022-08-08 | $305.55M derived: sum of 3 quarters · filed 2023-02-08 | $356.51M derived: sum of 4 quarters · filed 2023-02-08 |
| 2021-03-31 | $94.06M 10-Q · filed 2022-05-05 | $240.73M derived: sum of 2 quarters · filed 2023-02-08 | $291.70M derived: sum of 3 quarters · filed 2023-02-08 | $463.07M derived: sum of 4 quarters · filed 2023-02-08 |
| 2020-12-31 | $146.68M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-08 | $197.64M derived: sum of 2 quarters · filed 2023-02-08 | $369.02M derived: sum of 3 quarters · filed 2023-02-08 | $425.87M 10-K · filed 2023-02-08 |
| 2020-09-30 | $50.97M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $222.34M derived: sum of 2 quarters · filed 2021-11-04 | $279.19M 10-Q · filed 2021-11-04 | $402.24M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | $171.37M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $228.22M 10-Q · filed 2021-08-09 | $351.27M derived: sum of 3 quarters · filed 2022-02-28 | $480.87M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | $56.85M 10-Q · filed 2021-05-04 | $179.89M derived: sum of 2 quarters · filed 2022-02-28 | $309.49M derived: sum of 3 quarters · filed 2022-02-28 | $319.65M derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | $123.04M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $252.64M derived: sum of 2 quarters · filed 2022-02-28 | $262.80M derived: sum of 3 quarters · filed 2022-02-28 | $270.23M 10-K · filed 2022-02-28 |
| 2019-09-30 | $129.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $139.76M derived: sum of 2 quarters · filed 2020-11-09 | $147.19M 10-Q · filed 2020-11-09 | $211.06M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | $10.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | $17.59M 10-Q · filed 2020-08-05 | $81.46M derived: sum of 3 quarters · filed 2021-03-01 | $126.43M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-03-31 | $7.43M 10-Q · filed 2020-05-06 | $71.30M derived: sum of 2 quarters · filed 2021-03-01 | $116.27M derived: sum of 3 quarters · filed 2021-03-01 | $181.45M derived: sum of 4 quarters · filed 2021-03-01 |
| 2018-12-31 | $63.87M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $108.84M derived: sum of 2 quarters · filed 2021-03-01 | $174.02M derived: sum of 3 quarters · filed 2021-03-01 | $466.49M 10-K · filed 2021-03-01 |
| 2018-09-30 | $44.97M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $110.15M derived: sum of 2 quarters · filed 2019-11-07 | $402.62M 10-Q · filed 2019-11-07 | $426.24M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-06-30 | $65.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | $357.65M 10-Q · filed 2019-08-08 | $381.27M derived: sum of 3 quarters · filed 2020-02-27 | $421.71M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-03-31 | $292.47M 10-Q · filed 2019-05-09 | $316.09M derived: sum of 2 quarters · filed 2020-02-27 | $356.53M derived: sum of 3 quarters · filed 2020-02-27 | $416.94M derived: sum of 4 quarters · filed 2020-02-27 |
| 2017-12-31 | $23.62M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $64.06M derived: sum of 2 quarters · filed 2020-02-27 | $124.47M derived: sum of 3 quarters · filed 2020-02-27 | $176.46M 10-K · filed 2020-02-27 |
| 2017-09-30 | $40.44M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | $100.85M derived: sum of 2 quarters · filed 2018-11-06 | $152.84M 10-Q · filed 2018-11-06 | $205.49M derived: sum of 4 quarters · filed 2019-02-26 |
| 2017-06-30 | $60.41M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-01 | $112.39M 10-Q · filed 2018-08-01 | $165.04M derived: sum of 3 quarters · filed 2019-02-26 | $231.32M derived: sum of 4 quarters · filed 2019-02-26 |
| 2017-03-31 | $51.99M 10-Q · filed 2018-05-08 | $104.64M derived: sum of 2 quarters · filed 2019-02-26 | $170.91M derived: sum of 3 quarters · filed 2019-02-26 | $225.95M derived: sum of 4 quarters · filed 2019-02-26 |
| 2016-12-31 | $52.65M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26 | $118.92M derived: sum of 2 quarters · filed 2019-02-26 | $173.97M derived: sum of 3 quarters · filed 2019-02-26 | $304.93M 10-K · filed 2019-02-26 |
| 2016-09-30 | $66.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $121.32M derived: sum of 2 quarters · filed 2017-11-09 | $252.28M 10-Q · filed 2017-11-09 | $346.67M derived: sum of 4 quarters · filed 2018-02-27 |
| 2016-06-30 | $55.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-07 | $186.01M 10-Q · filed 2017-08-07 | $280.39M derived: sum of 3 quarters · filed 2018-02-27 | $454.46M derived: sum of 4 quarters · filed 2018-02-27 |
| 2016-03-31 | $130.96M 10-Q · filed 2017-05-04 | $225.35M derived: sum of 2 quarters · filed 2018-02-27 | $399.41M derived: sum of 3 quarters · filed 2018-02-27 | $455.94M derived: sum of 4 quarters · filed 2018-02-27 |
| 2015-12-31 | $94.39M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | $268.45M derived: sum of 2 quarters · filed 2018-02-27 | $324.98M derived: sum of 3 quarters · filed 2018-02-27 | $379.78M 10-K · filed 2018-02-27 |
| 2015-09-30 | $174.06M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-04 | $230.59M derived: sum of 2 quarters · filed 2016-11-04 | $285.39M 10-Q · filed 2016-11-04 | $352.30M derived: sum of 4 quarters · filed 2017-03-09 |
| 2015-06-30 | $56.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-08 | $111.33M 10-Q · filed 2016-08-08 | $178.23M derived: sum of 3 quarters · filed 2017-03-09 | $181.86M derived: sum of 4 quarters · filed 2017-03-09 |
| 2015-03-31 | $54.80M 10-Q · filed 2016-05-06 | $121.70M derived: sum of 2 quarters · filed 2017-03-09 | $125.33M derived: sum of 3 quarters · filed 2017-03-09 | $127.91M derived: sum of 4 quarters · filed 2017-03-09 |
| 2014-12-31 | $66.91M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-09 | $70.54M derived: sum of 2 quarters · filed 2017-03-09 | $73.11M derived: sum of 3 quarters · filed 2017-03-09 | $95.53M 10-K · filed 2017-03-09 |
| 2014-09-30 | $3.63M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-12 | $6.20M derived: sum of 2 quarters · filed 2015-08-07 | $28.62M 10-Q · filed 2014-11-12 | |
| 2014-06-30 | $2.57M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-07 | $24.99M 10-Q · filed 2015-08-07 | ||
| 2014-03-31 | $22.41M 10-Q · filed 2015-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |